Neuroimaging as endpoints in clinical trials: Are we there yet? Perspective from the first Provence workshop

Molecular Psychiatry

Volumn 16, Issue 11, 2011, Pages 1064-1066

  Valenzuela, M ^a,b   Bartres Faz D ^c   Beg, F ^d   Fornito, A ^e   Merlo Pich, E ^f   Muller U ^g   Ongur D ^h,i   Toga, A W ^j   Yucel M ^e  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF BARCELONA   (Spain)

^d SIMON FRASER UNIVERSITY   (Canada)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h MCLEAN HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; RILUZOLE;

ALZHEIMER DISEASE; BIPOLAR DISORDER; BRAIN SIZE; COGNITION; ENDOPHENOTYPE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL DETECTION;

BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ENDPOINT DETERMINATION; HUMANS; INDIVIDUALIZED MEDICINE; NEUROIMAGING; ORGAN SIZE; TREATMENT OUTCOME;

EID: 80054872027     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.62     Document Type: Note

References (10)

1. Kohannim O et al. Neurobiol Aging 2010; 31: 1429-1442.
2. Holland D et al. Proc Natl Acad Sci U S A 2009; 106: 20954-20959.
3. Stein JL et al. Neuroimage 2010; 53: 1160-1174.
4. Paulus MP, Stein MB. Neuropsychol Rev 2007; 17: 179-188.
5. Furmark T et al. J Neurosci 2008; 28: 13066-13074.
6. Jack CR et al. Lancet Neurol 2010; 9: 119-128.
7. Brennan BP et al. Neuropsychopharmacology 2010; 35: 834-846.
8. Bullmore E, Sporns O. Nat Rev Neurosci 2009; 10: 186-198.
9. Thomas AG et al. Neuroimage 2009; 48: 117-125.
10. Fox NC et al. Neurology 2005; 64: 1563-1572.